Welcome to our dedicated page for Haemonetics Mass news (Ticker: HAE), a resource for investors and traders seeking the latest updates and insights on Haemonetics Mass stock.
Haemonetics Corporation reports recurring developments across its global medical technology business, including financial results, investor conference participation, product studies and U.S. regulatory actions. The company’s solutions include hospital technologies, end-to-end plasma collection technologies for plasma centers and products used by blood centers to collect blood components.
Company news frequently centers on the VASCADE MVP and VASCADE MVP XL venous vascular closure systems, the NexSys PCS Plasma Collection System and Persona technology. Updates also cover FDA approvals or 510(k) clearances, clinical evidence supporting device use, earnings releases and presentations, and communications tied to the company’s plasma, blood center and hospital markets.
Haemonetics Corporation (NYSE: HAE) will present at the Morgan Stanley Virtual Global Healthcare Conference on September 9, 2021, at 8:45 a.m. ET. Chris Simon, the President and CEO, will lead the presentation, which can be accessed live via webcast at Morgan Stanley's website. Haemonetics focuses on innovative medical products that improve patient care and lower healthcare costs, particularly in blood and plasma component collection, surgical suites, and hospital transfusion services. More information can be found on their official website.
Haemonetics Corporation (NYSE: HAE) announced that the financial results for its first quarter of fiscal 2022, ending July 3, 2021, are now available on its Investor Relations website. A conference call is scheduled for August 11, 2021, at 8:00 a.m. ET to discuss these results, with access details provided. The company emphasized its commitment to improving patient care through innovative medical solutions. Further information is accessible via their investor portal.
Haemonetics Corporation (NYSE: HAE) announced Lloyd E. Johnson's election to its Board of Directors and the appointment of Ellen Zane as the new independent Chair. Johnson, a seasoned finance leader with over 35 years of experience, previously held senior roles at Accenture and Delphi Automotive. Zane succeeds Richard Meelia, who retired following the 2021 Annual Meeting. This leadership transition aims to bolster Haemonetics' strategies for enhancing shareholder value.
Summary not available.
Haemonetics Corporation (NYSE: HAE) announced it will release its first quarter fiscal year 2022 financial results on August 11, 2021, at 6:00 am EDT. Following this, a conference call will take place at 8:00 am EDT on the same day to discuss the results and answer questions. Investors can access the call via a toll-free number or through an online webcast. A replay will be available for one year starting from August 11, 2021, at 11:00 am EDT.
Haemonetics Corporation (NYSE: HAE) revealed its financial results for the fourth quarter of fiscal 2021, which ended on April 3, 2021. The results can be accessed on the company's Investor Relations website. Following the release, a conference call and webcast will be held on May 13, 2021, at 8:00 a.m. ET, allowing investors to engage with management and learn more about the results. The company’s offerings support healthcare improvements in blood and plasma collection, surgical services, and hospital transfusions. Detailed earnings information is also available through direct links provided in the announcement.
Haemonetics Corporation (NYSE: HAE) announces the publication of full results from the IMPACT trial in the journal TRANSFUSION. This multicenter study analyzed plasma collection methods involving 3,443 donors and 23,137 donations. The trial compared NexSys PCS® with YES® Technology and its Persona® Technology, achieving an 8.2% increase in plasma yield without compromising safety. The NexSys PCS® system with Persona® received FDA clearance in 2020. Plasma is vital for therapies for conditions like hemophilia and primary immunodeficiency, affecting approximately 750,000 patients across North America and Europe.
Haemonetics Corporation (NYSE: HAE) will release its fourth quarter and fiscal year 2021 financial results on May 13, 2021, at 6:00 am EDT. An investor conference call will follow at 8:00 am EDT to discuss the results. Interested participants can join the call via a toll-free number for U.S. and Canada or an international line, with a required conference ID of 8694785. A live webcast will also be available on the company's investor relations website, and a replay will be accessible for one year starting at 11:00 am EDT on the same day.
Haemonetics Corporation (NYSE: HAE) announced that CSL Plasma will not renew their Supply Agreement for PCS2® Plasma Collection System devices in the U.S., effective June 2022. This decision, driven by CSL's internal strategy, will affect approximately $117 million in revenue, which is 11.8% of Haemonetics' total revenue. The company anticipates a $25 million impairment charge and an additional $7 million in expenses in Q4 FY2021. Despite this, Haemonetics remains committed to supporting CSL in other markets and expects continued growth in U.S. plasma collections.
Haemonetics Corporation (NYSE: HAE) has priced a private offering of $435 million aggregate principal amount of 0.00% Convertible Senior Notes due March 2026. This offering, increased from a previous $425 million, is set to close on March 5, 2021. The notes will not bear regular interest and are convertible into common stock at an initial price of approximately $175.34, a 40% premium over the last reported sale. Haemonetics estimates net proceeds of about $423.3 million, for debt reduction and other corporate purposes.